Abnormal expression of the Notch and Wnt/β-catenin signaling pathways in stem-like ALDHhiCD44+ cells correlates highly with Ki-67 expression in breast cancer

干细胞样 ALDHhiCD44+ 细胞中 Notch 和 Wnt/β-catenin 信号通路的异常表达与乳腺癌中 Ki-67 的表达高度相关

阅读:9
作者:Junwei Cui, Peng Li, Xiaoling Liu, Hui Hu, Wei Wei

Abstract

Previous studies have reported that breast cancer stem cells may be closely associated with tumor metastasis, recurrence, and even the failure of chemotherapy and radiotherapy. The aim of the present study was to investigate whether important cell signaling pathways associated with drug resistance are activated in stem-like acetaldehyde dehydrogenase (ALDH)hi cluster of differentiation (CD)44+ cells, and to analyze the association between ALDHhiCD44+ cells and specific pathological features. ALDHhiCD44+ cells and non-stem-like ALDHlowCD44+ cells were separated from MDA-MB-231 cells by fluorescence-activated cell sorting, and the mRNA expression levels of Notch1 and β-catenin were estimated by performing quantitative polymerase chain reaction in the stem-like and non-stem-like cells. Line correlation analysis was used to evaluate the correlation between an immunohistochemical panel of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67, and ALDHhiCD44+ cells from patients with invasive breast carcinoma. The mRNA levels of Notch1 and β-catenin were significantly higher in the ALDHhiCD44+ cells compared with those in the ALDHlowCD44+ cells (P<0.05); furthermore, the present study determined a high correlation (P<0.05) between the ALDHhiCD44+ cells and Ki-67 expression (P=0.007), but no correlation (P≥0.05) with ER (P=0.065), PR (P=0.107) and HER2 (P=0.050). Overall, these data clearly indicate that ALDHhiCD44+ cells may serve as novel diagnostic and prognostic factors in breast cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。